GLP-1 vs GLP-3: Why People Search for a Drug Class That Doesn't Exist

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 10 sources cited

Key Takeaways

• "GLP-3" is a popular term that has no formal medical or regulatory meaning
• The real classification distinguishes single-receptor (GLP-1), dual-receptor (GLP-1/GIP, GLP-1/glucagon), and triple-receptor (GLP-1/GIP/glucagon) agonists
• Retatrutide is the most commonly meant drug when people say "GLP-3"; it is the only major triple agonist in advanced development
• GLP-2 is a real but separate hormone used in a different indication (short bowel syndrome via teduglutide), not weight loss
• Retatrutide is investigational and not FDA-approved. FormBlends does not sell or supply retatrutide

Direct answer

There is no formal drug class called GLP-3. The phrase is colloquial shorthand, often used to refer to retatrutide, a triple-receptor agonist of GLP-1, GIP, and glucagon. The accurate way to describe these drugs is by what they activate. Semaglutide is a single-receptor GLP-1 agonist. Tirzepatide is a dual GLP-1/GIP agonist. Retatrutide is a triple GLP-1/GIP/glucagon agonist. CagriSema is a fixed-ratio combination of semaglutide and cagrilintide (GLP-1 plus amylin). GLP-2 is a real but separate hormone with a different therapeutic role.

Table of contents

1. The naming confusion in plain English
2. The actual hormone classification
3. What "GLP-1" really refers to
4. The dual-agonist category
5. The triple-agonist category (the one people call "GLP-3")
6. GLP-2: a real hormone, unrelated
7. Why the colloquial naming spread
8. Drug-by-drug class assignment
9. What it means for patient decisions
10. The contrary view: is colloquial naming harmful?
11. FAQ
12. Sources

The naming confusion in plain English

Walk into a Reddit thread or a social media discussion about new weight-loss drugs and you'll see "GLP-1," "GLP-2," and "GLP-3" used as if they were a numbered progression of drug generations. They are not.

The confusion has a logic to it. Semaglutide is a "GLP-1." Tirzepatide is sometimes called "the next generation." Retatrutide is "the one after that." Numbering them makes intuitive sense as a way to describe drug evolution. But the numbers don't correspond to anything real in pharmacology.

What the numbers actually refer to in the medical literature:

• GLP-1. A hormone (glucagon-like peptide-1) and the receptor it binds. Drugs that activate this receptor are GLP-1 receptor agonists. Semaglutide, liraglutide, dulaglutide, exenatide.
• GLP-2. A different hormone (glucagon-like peptide-2). Drugs that activate this receptor are GLP-2 receptor agonists. Teduglutide (Gattex), used for short bowel syndrome.
• GLP-3. Does not exist as a hormone or receptor.

The "next-generation" weight-loss drugs (tirzepatide, retatrutide, CagriSema, survodutide, mazdutide) are not GLP-2 or GLP-3. They are multi-receptor agonists that include GLP-1 plus other receptors.

The actual hormone classification

To understand what these drugs do, it helps to know the actual hormones involved.

Obesity drugs work by activating combinations of GLP-1, GIP, glucagon, and amylin receptors. None of them activates GLP-2.

What "GLP-1" really refers to

The "GLP-1 receptor agonist" category includes:

• Semaglutide. Weekly injectable (Ozempic, Wegovy) and oral (Rybelsus). The most-prescribed GLP-1 agonist globally.
• Liraglutide. Daily injectable (Saxenda, Victoza). Older molecule, approved earlier.
• Dulaglutide. Weekly injectable (Trulicity). Approved for diabetes.
• Exenatide. Twice-daily and weekly injectable formulations (Byetta, Bydureon). Older.
• Investigational oral GLP-1s. Orforglipron, oral semaglutide 50 mg, others.

These drugs all activate one receptor: GLP-1. They differ in dosing schedule, route of administration, and pharmacokinetics, but they share the single-receptor mechanism.

The dual-agonist category

Dual agonists activate two receptors. Two distinct sub-categories exist:

GLP-1 / GIP dual agonists. The "twincretin" class. Tirzepatide is the only approved drug in this category. SURMOUNT-1 reported ~22.5% weight loss at 15 mg.

GLP-1 / glucagon dual agonists. The "glucagon co-agonist" class. Survodutide (investigational, phase 3), mazdutide (approved in China only), and pemvidutide (earlier phase) belong here. The glucagon component adds hepatic fat reduction and energy expenditure.

The two dual-agonist sub-categories have similar overall efficacy in trials (low-to-mid 20% weight loss at maximum doses) but different side-effect profiles and indication breadth. Tirzepatide has stronger diabetes evidence; survodutide has the distinctive MASH liver-disease story.

The triple-agonist category (the one people call "GLP-3")

Triple agonists activate GLP-1, GIP, and glucagon receptors. Retatrutide is the only major triple agonist in advanced development. Phase 2 produced ~24% weight loss at 48 weeks, the highest reported for any obesity drug in any trial.

The "GLP-3" label, when used for retatrutide:

• Captures the intuition that retatrutide is "the next thing" after GLP-1 and GLP-1/GIP duals
• Ignores the fact that GIP and glucagon are different hormones, not numbered versions of GLP
• Conflates pharmacological mechanism with marketing simplification

The accurate terminology is "triple-receptor agonist" or "GLP-1/GIP/glucagon agonist" or "tri-agonist." These names tell you what the drug does.

GLP-2: a real hormone, unrelated

GLP-2 is a real hormone, secreted from intestinal L cells alongside GLP-1. Its primary actions are on intestinal mucosa: it stimulates crypt cell proliferation, increases villus height, and improves absorption.

The therapeutic drug in the GLP-2 receptor agonist class is teduglutide (Gattex), approved by the FDA in 2012 for short bowel syndrome. Patients with short bowel syndrome have lost substantial intestinal length due to surgery (e.g., for Crohn's disease, ischemia, or congenital conditions); teduglutide helps remaining intestine adapt and absorb more nutrients.

Teduglutide is not used for weight loss. The mechanism does not produce weight loss; if anything, it improves absorption and supports weight maintenance in malabsorption.

People searching for "GLP-2 for weight loss" are usually conflating the GLP-2 name with the broader GLP-1 class. The drugs are not equivalent.

Why the colloquial naming spread

Three drivers explain why "GLP-2" and "GLP-3" caught on as informal terms despite being inaccurate:

Driver 1: Pattern matching. The brain looks for numbered progressions. If GLP-1 is the first generation, the natural next labels are GLP-2 and GLP-3. The instinct is wrong but understandable.

Driver 2: Marketing simplification. "Next-generation GLP-1" is awkward. "Triple-receptor agonist" is technical. "GLP-3" is short, intuitive, and memorable. Casual media adopts it.

Driver 3: Confusion with actual drug classes. Some readers genuinely believe GLP-2 and GLP-3 are recognized drug categories. Health-content sites occasionally use the terms, reinforcing the misconception.

The result is a substantial search-volume gap between the technical terms (tri-agonist, multi-receptor agonist) and the colloquial ones (GLP-2, GLP-3). The technical terms describe reality; the colloquial ones describe how people think about reality.

Drug-by-drug class assignment

The accurate class assignments for the drugs people commonly ask about:

What it means for patient decisions

For most patients, the colloquial naming doesn't change practical decisions. What matters is:

• The drug's actual efficacy and side-effect profile
• FDA approval status and availability
• Insurance coverage
• Comorbid indications (diabetes, cardiovascular disease, MASH, OSA)

The classification system matters more for understanding what a drug does mechanistically and how it compares to alternatives. "Tirzepatide adds GIP to GLP-1" is more informative than "tirzepatide is a GLP-2."

For decisions about specific drugs:

• Ozempic and Wegovy are the same molecule (semaglutide) at different doses
• Tirzepatide adds a different receptor (GIP) to GLP-1 activity
• Retatrutide adds two different receptors (GIP and glucagon) to GLP-1 activity
• Compounded versions of approved drugs are not FDA-approved
• Investigational drugs are not legally available outside clinical trials

The contrary view: is colloquial naming harmful?

Two perspectives on the GLP-2/GLP-3 colloquial usage:

Case against the colloquial naming. It spreads misinformation. Patients searching for "GLP-2" may end up at content about teduglutide, which is irrelevant to weight loss. The numbered hierarchy implies a linear progression that doesn't reflect drug pharmacology. Marketing simplification can become a barrier to understanding.

Case in favor of pragmatic colloquial use. Most patients don't need to understand receptor pharmacology to make medication decisions. Simplified language enables more people to engage with their treatment. As long as the colloquial term doesn't lead to clinically incorrect decisions, the simplification is acceptable.

The middle-ground view: use accurate terminology when it matters (clinical decisions, comparing drugs by mechanism), but accept colloquial usage when it's just shorthand. Knowing that "GLP-3" colloquially means "retatrutide-style triple agonist" is useful, even if the term is technically wrong.

Decision framework

If you encounter "GLP-3" in health content: the writer almost always means retatrutide or another triple-agonist drug. Translate it mentally.

If you encounter "GLP-2" in obesity content: the writer is probably making a mistake. There is no "GLP-2" for weight loss. The real GLP-2 drug (teduglutide) is for a different condition.

If you're considering a triple agonist: the only one in advanced development is retatrutide, and it is not FDA-approved. Clinical trial enrollment is the only legitimate pre-approval route.

If you're comparing drugs: compare by receptor mechanism, weight-loss efficacy, side-effect profile, and approval status, not by numbered class labels.

Compounded medication note for this topic

For GLP-1 vs GLP-3: Why People Search for a Drug Class That Doesn't Exist, keep the pharmacy distinction clear: when compounded semaglutide or tirzepatide is prescribed, it is prepared for an individual patient by a licensed 503A compounding pharmacy. Compounded preparations are not FDA-approved drug products and are not interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound.

The practical question is not whether a compounded medication is a brand substitute. It is whether the prescription, pharmacy label, concentration, follow-up plan, and adverse-event support are clear enough for your specific medical history.

FAQ

Is GLP-3 a real drug? No. "GLP-3" is colloquial shorthand for triple-receptor agonists like retatrutide.

Is tirzepatide a GLP-2? No. Tirzepatide is a GLP-1/GIP dual agonist. "GLP-2" is a different hormone.

What's the difference between GLP-1 and GIP? Both are intestinal incretin hormones, but they come from different cell types and bind different receptors. Both enhance insulin secretion in response to meals.

Is retatrutide GLP-3? Colloquially yes; pharmacologically it's a GLP-1/GIP/glucagon triple agonist.

What's the next class after triple agonists? No fourth-receptor obesity drug is in advanced development. Future innovation may involve amylin combinations (CagriSema is one example), entirely different mechanisms (bimagrumab targets activin receptors), or more refined receptor-selective designs.

Is CagriSema a triple agonist? No. CagriSema is a fixed-ratio combination of two single-receptor drugs: semaglutide (GLP-1) and cagrilintide (amylin). Two molecules, not one molecule with multiple receptors.

Is amylin the same as glucagon? No. Different hormones from different sources. Amylin comes from pancreatic beta cells (alongside insulin). Glucagon comes from pancreatic alpha cells. They have different receptors and different effects.

What does "incretin" mean? Incretins are gut-derived hormones that enhance insulin secretion in response to nutrients. GLP-1 and GIP are the two main incretins.

Are there any GLP-4 drugs? No. There is no GLP-4 hormone or drug class.

Why do drug companies use confusing names? Generic drug names follow a rough convention: GLP-1 class drugs often end in "-glutide" (semaglutide, liraglutide), tirzepatide-style dual agonists have varied endings, and triple agonists may follow new patterns. The naming reflects molecular structure and discovery history, not patient-facing logic.

Is GLP-1 receptor activity bad for the kidneys? No. GLP-1 receptor agonists are generally renal-friendly and have shown nephroprotective effects in cardiovascular outcomes trials.

Related guides

• What Is Cagrilintide for Men? Why People Search This Way
• GLP-3 and Retatrutide: Why People Call It That (In-Depth)
• Retatrutide and Glp-3 What People Mean
• GLP-3 and Retatrutide: Why People Call It That (FAQ)

Sources

1. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018.
2. Coskun T et al. LY3437943 (retatrutide), a novel triple agonist: preclinical pharmacology. Cell Metabolism. 2022.
3. Jastreboff AM et al. Triple-Hormone Receptor Agonist Retatrutide for Obesity. NEJM. 2023.
4. Jastreboff AM et al. Tirzepatide for Obesity (SURMOUNT-1). NEJM. 2022.
5. Wilding JPH et al. Once-Weekly Semaglutide (STEP 1). NEJM. 2021.
6. Drucker DJ. The Cardiovascular Biology of Glucagon-like Peptide-1. Cell Metabolism. 2016.
7. FDA. Gattex (Teduglutide) Prescribing Information. 2012, with subsequent revisions.
8. le Roux CW et al. Survodutide (GLP-1/glucagon) phase 2. Lancet. 2024.
9. Garvey WT et al. CagriSema REDEFINE-1. ObesityWeek 2024.
10. Endocrine Society. Pharmacological Management of Obesity. 2024 update.

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth platform connecting patients with independent licensed prescribers. We provide educational content to help patients understand their options. We do not provide medical advice and we do not sell or supply investigational drugs.

Terminology Notice. The terms "GLP-2" and "GLP-3" as used in some consumer health writing for weight-loss drugs are colloquial and not formal pharmacological classifications. Drug class assignment in this article follows accepted medical and regulatory terminology.

Investigational Drug Notice. Retatrutide and other triple- or dual-agonist drugs referenced as colloquial "GLP-3" or "GLP-2" alternatives are investigational and not FDA-approved as of May 2026.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Saxenda, Victoza, and Trulicity are registered trademarks of Novo Nordisk A/S and Eli Lilly and Company. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Gattex is a registered trademark of Takeda Pharmaceutical Company. FormBlends is not affiliated with these companies.